Targeting SNAI1-Mediated Colorectal Cancer Chemoresistance and Stemness by Sphingosine Kinase 2 Inhibition
SNAI1/SPHK2 signaling mediates cancer stemness and 5FU resistance, implicating S1P as a therapeutic target for CRC. The S1P inhibitor ABC294640 holds potential as a therapeutic agent to target CSCs in therapy refractory CRC.
Authors
- Alhaji Janneh
- Besim Öğretmen (ORCID: https://orcid.org/0000-0002-1019-5660)
- Ernest Ramsay Camp (ORCID: https://orcid.org/0000-0003-0005-7536)
- Jiangling Dong (ORCID: https://orcid.org/0000-0001-9742-2469)
- Harinarayanan Janakiraman (ORCID: https://orcid.org/0000-0002-3043-2352)
- Zachary Gao
- Scott A. Becker (ORCID: https://orcid.org/0000-0003-0194-4874)
- Yun Zhu (ORCID: https://orcid.org/0000-0003-3531-3544)
Institutions
- Michael E. DeBakey VA Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Emory University (US)
- Medical University of South Carolina (US)
- Baylor College of Medicine (US)
- Children's Cancer Center (US)
Publication Details
- Journal
- World Journal of Oncology
- Published
- 2024-09-23
- DOI
- https://doi.org/10.14740/wjon1890
- Citations
- 3
- Primary Topic
- Sphingolipid Metabolism and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health